RxDoctor Payments Data

Asim Gilani, MD

Family Medicine · Brick, NJNPI 1598756173

Payments from drug & device makers

$7,219in general payments, 2019–2025

Across 449 payments — averaging $16.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novartis$452
  • Novo Nordisk$443
  • Lilly USA, LLC$438
  • Daiichi Sankyo Inc.$400
  • Pfizer$396
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$7,13099%
  • Education$891%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,219 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$552,361
Medicare patients
1,129
Services billed
7,046

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban163$126,839
OzempicSemaglutide54$84,016
JardianceEmpagliflozin73$82,989
XareltoRivaroxaban63$74,417
JanuviaSitagliptin Phosphate64$73,777
FarxigaDapagliflozin Propanediol54$58,689
MounjaroTirzepatide35$46,617
WegovySemaglutide22$30,994
JanumetSitagliptin Phos/Metformin Hcl19$27,913
Icosapent Ethyl51$27,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$20,853
EntrestoSacubitril/Valsartan13$17,088
Dexlansoprazole DrDexlansoprazole25$15,006
MyrbetriqMirabegron11$13,596
SynthroidLevothyroxine Sodium149$11,018

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$396$126,839163 claims
Novo NordiskOzempic, Wegovy$443$115,01176 claims
MerckJanuvia, Janumet$119$101,69083 claims
Boehringer IngelheimJardiance$185$82,98973 claims
Johnson & JohnsonXarelto$225$74,41763 claims
AstraZenecaFarxiga$277$58,68954 claims
Lilly USA, LLCMounjaro$438$46,61735 claims
GSKTrelegy Ellipta, Breo Ellipta$14$31,66737 claims
NovartisEntresto$452$17,08813 claims
Astellas Pharma US IncMyrbetriq$231$13,59611 claims
AbbVieSynthroid$1,322$11,018149 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$47$8,713662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Brick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →